NewslettersDermal Cell NewsHuman Immunology News Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase I/IIa Clinical Trial for EVX-02 By Danielle Corrigan - May 10, 2022 0 Evaxion Biotech A/S announced that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase I/IIa clinical trial of EVX-02 in adjuvant melanoma. [Evaxion Biotech A/S] Press Release